Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Deucravacitinib in SLE
NCT03920267Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2019
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2 trial of deucravacitinib in systemic lupus erythematosus (SLE) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events and Treatment Emergent Serious Adverse Events up to 42 months, Number of Participants With Abnormalities in Vital Signs up to 42 months and 1 more. Started Mar 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03920267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920267.